Comparative study of the effectiveness of combination therapies based on atemisinine in Dassa Zounme and Parakou: case of Artemether lumefantrine and Artesunate amodiaquine

The National Malaria Control Program recommended in 1993, the use of Chloroquina (CQ) as first line drug for malaria treatment, and sulfadoxin pyrimethamin as second drug. After years, Benin knows resistance about these antimalarials. Quinina was to treat gravities. In 2004, the strategy of treatment changed. Treatment of malaria cases is based on use of arteminisinia therapeutic combination. The goal of this study is to be sure that these drugs are efficace before general use in the country and in some regions as Dassa Zounmè where the resistance is up (61. 3% for Chloroquina CQ and 45.9% for SP in 2002).The study is based on: comparison of therapeutic efficacy of artemether Lumefantrine and Artesunate Amodiaquine. Results show that all of the tested drugs have good therapeutic efficacy. Most important rate failure is in Dassa Zounmè (33, 86%) than Parakou (23, 44%). They are parasitologic failure and are probably due to the reinfestation of children. Two drugs have a good parasitological clearance and eliminate fever after 2 days of treatment. Published by the International journal of Microbiology and Mycology (IJMM

Capacity Development through the US President’s Malaria Initiative–Supported Antimalarial Resistance Monitoring in Africa Network

Antimalarial drug resistance is an evolving global health security threat to malaria control. Early detection of Plasmodium falciparum resistance through therapeutic efficacy studies and associated genetic analyses may facilitate timely implementation of intervention strategies. The US President’s Malaria Initiative–supported Antimalarial Resistance Monitoring in Africa Network has assisted numerous laboratories in partner countries in acquiring the knowledge and capability to independently monitor for molecular markers of antimalarial drug resistance

Laboratory capacity assessments in 25 African countries at high risk of yellow fever, August-December 2018.

INTRODUCTION: accurate and timely laboratory diagnosis of yellow fever (YF) is critical to the Eliminate Yellow Fever Epidemics (EYE) strategy. Gavi, the Vaccine Alliance recognized the need to support and build capacity in the national and regional laboratories in the Global YF Laboratory Network (GYFLN) as part of this strategy. METHODS: to better understand current capacity, gaps and needs of the GYFLN laboratories in Africa, assessments were carried out in national and regional reference laboratories in the 25 African countries at high risk for YF outbreaks that were eligible for new financial support from Gavi. RESULTS: the assessments found that the GYFLN in Africa has high capacity but 21% of specimens were not tested due to lack of testing kits or reagents and approximately 50% of presumptive YF cases were not confirmed at the regional reference laboratory due to problems with shipping. CONCLUSION: the laboratory assessments helped to document the baseline capacities of these laboratories prior to Gavi funding to support strengthening YF laboratories